179 filings
Page 4 of 9
8-K
gct99d 5ww
16 Mar 20
Entry into a Material Definitive Agreement
4:30pm
8-K
n13wxr s9g
10 Feb 20
Other Events
4:54pm
8-K
umsgg1m zra89w35sv5
29 Aug 19
Departure of Directors or Certain Officers
4:30pm
8-K
qa7c3vt3 was6oqif
29 Aug 19
Entry into a Material Definitive Agreement
6:45am
8-K
zxx s66xgkghk
7 Aug 19
Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development
6:43am
8-K
28t9jqgx
7 Jun 19
Submission of Matters to a Vote of Security Holders
2:19pm
8-K
zx4eimpi
29 May 19
Rexahn Announces Move to Nasdaq
12:56pm
8-K
x7vfwi
16 Apr 19
Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China
8:03am
8-K
hkdxhynyztybo
12 Apr 19
Amendments to Articles of Incorporation or Bylaws
8:15am
8-K
gws0 dn6gtljcc
26 Mar 19
Submission of Matters to a Vote of Security Holders
4:13pm
8-K
imquyr3tikbpwrpe24y
11 Mar 19
Regulation FD Disclosure
6:54am
8-K
9ucqzcspalg 8jt14ti5
6 Mar 19
Departure of Directors or Certain Officers
4:23pm
8-K
g4a90
1 Mar 19
Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
5:10pm
8-K
708xrr0rbydgxrjym9
25 Jan 19
Entry into a Material Definitive Agreement
4:51pm
8-K
5a1b3
22 Jan 19
Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer
4:48pm
8-K
of148
3 Dec 18
Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors
4:53pm
8-K
z3gxrv0l03an
16 Nov 18
Rexahn Pharmaceuticals Announces Leadership Transition
4:45pm
8-K
2m6j5xkk2gda 3tx0n4
19 Oct 18
Entry into a Material Definitive Agreement
9:19am
8-K
oyqae8sxs6p2
30 Aug 18
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
ww48pkx7 3w7l79aa
21 Aug 18
Entry into a Material Definitive Agreement
12:00am